Medically reviewed by Bandela Mgoqi (B.Pharm, M.Pharm, MPS). Last updated on September 17, 2026.
VASOPRESSIN CIPLA contains vasopressin – a polypeptide hormone. It is an 'antidiuretic' which helps to prevent excess loss of water in your urine and narrows some blood vessels in the body.
VASOPRESSIN CIPLA is indicated to increase blood pressure in adults with vasodilatory shock who continue to have decreased blood pressure despite fluids and catecholamines.
Do not receive VASOPRESSIN CIPLA
Tell your doctor or health care provider before being given VASOPRESSIN CIPLA:
Always tell your health care provider if you are taking any other medicine. (This includes all complementary or traditional medicines).
Catecholamines such as - dopamine, norepinephrine (nor adrenaline), and epinephrine (adrenaline) –may result in an additional increase of blood pressure and heart rate, Your doctor may adjust the dosage of VASOPRESSIN CIPLA while monitoring your blood pressure.
Nonsteroidal anti-inflammatory drugs (NSAIDs) such as Indomethacin may prolong the effect of VASOPRESSIN CIPLA leading to greater pumping of the blood by the heart and increase in the resistance to blood flow.
The ganglionic blocking agent tetra-ethyl ammonium increases the effect of VASOPRESSIN CIPLA by 20 % in healthy individuals - Your doctor may adjust the dosage of VASOPRESSIN CIPLA while monitoring your blood pressure.
Antidepressants such as selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, and other medicines like haloperidol, chlorpropamide, enalapril, methyldopa, pentamidine, vincristine, cyclophosphamide, ifosfamide, felbamate may increase the effects of VASOPRESSIN CIPLA on narrowing blood vessels and increasing blood pressure, as well as controlling urine output. Your doctor may adjust the dosage of VASOPRESSIN CIPLA while monitoring your blood VASOPRESSIN CIPLA.
Certain medicines like demeclocycline, lithium, foscarnet, clozapine may decrease the effect of VASOPRESSIN CIPLA; your doctor will monitor the same and adjust the dose of VASOPRESSIN CIPLA accordingly.
No data available.
VASOPRESSIN CIPLA may produce contraction of uterine muscle that could threaten the continuation of pregnancy.
If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, please consult your doctor, pharmacist or other health care provider for advice before taking VASOPRESSIN CIPLA.
No data available. It is not always possible to predict to what extent VASOPRESSIN CIPLA may interfere with the daily activities of a patient. Patients should ensure that they do not engage in the above activities until they are aware of the measure to which VASOPRESSIN CIPLA affects them.
VASOPRESSIN CIPLA contains dextrose. VASOPRESSIN CIPLA contains dextrose anhydrous which may have an effect on the control of your blood sugar if you have diabetes mellitus.
Route of administration - Parenteral Injection
You will not be expected to give yourself VASOPRESSIN CIPLA. It will be given to you by a person who is qualified to do so.
If you receive more VASOPRESSIN CIPLA than you should
Since a health care provider will administer VASOPRESSIN CIPLA, he / she will control the dosage. However, in the event of overdosage your doctor will manage the overdosage.
If you forget to take VASOPRESSIN CIPLA
Since a health care provider will administer VASOPRESSIN CIPLA, it is unlikely that the dose will be missed.
VASOPRESSIN CIPLA can have side effects. Not all side effects reported for VASOPRESSIN CIPLA are included in this leaflet. Should your general health worsen or if you experience any untoward effects while taking VASOPRESSIN CIPLA, please consult your health care provider for advice.
If any of the following happens, stop taking VASOPRESSIN CIPLA and tell your doctor immediately or go to the casualty department at your nearest hospital:
Frequency unknown - frequency cannot be estimated from the available data.
If you notice any side effects not mentioned in this leaflet, please inform your doctor or pharmacist.
If you get side effects, talk to your doctor or, pharmacist. You can also report side effects to SAHPRA via the via the Med Safety APP (Medsafety X SAHPRA) and eReporting platform (who-umc.org) found on the SAHPRA website, or to Cipla Medpro (Pty) Ltd. by e-mail: [email protected] or telephone: 080 222 6662 (toll free). By reporting side effects, you can help provide more information on the safety of VASOPRESSIN CIPLA.
Ideal Storage: Store between 2 °C and 8 °C (36 °F and 46 °F). Do not freeze.
Shelf life of the product is 24 months when stored at 2 to 8°C from the date of manufacturing. Vials may be held up to 6 months upon removal from refrigeration to room temperature storage conditions (20 °C to 25 °C [68 °F to 77 °F], USP – United States Pharmacopeia Controlled Room Temperature), anytime within the labelled shelf life. Once removed from refrigeration, unopened vial should be marked to indicate the revised 6-months expiration date. If the manufacturer’s original expiration date is shorter than the revised expiration date, then the shorter date must be used. Do not use VASOPRESSIN CIPLA, beyond the manufacturer’s expiration date stamped on the vial.
The storage conditions and expiration periods are summarized in the following table.
| Pack | Unopened Refrigerated 2°C to 8°C (36°F to 46°F) | Unopened Room Temperature 20°C to 25°C (68°F to 77°F) | Do not store above 25°C (77°F) | Opened (After First Puncture) |
|---|---|---|---|---|
| 100 mL Vial | Until manufacturer expiration date | 6 months or until manufacturer expiration date, whichever is earlier | Not applicable | Do not use after the expiry date stated on the packaging. |
The Vasopressin 40 units/100 ml Solution professional information leaflet below is the property of Cipla Medpro and is provided on Somayeza exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Somayeza serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
The patient information text is available above. Load the original PDF only when you need it.